RxDoctor Payments Data

Osamamwode Ogbeiwi, NP

Psychiatric/Mental Health · Brea, CANPI 1609047166

Payments from drug & device makers

$512in general payments, 2019–2025

Across 14 payments — averaging $36.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$131
  • Alkermes, Inc.$125
  • AbbVie$98
  • Johnson & Johnson$59
  • Neurocrine Biosciences, Inc.$47
  • Neuronetics, Inc.$37
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$512 in reported general payments places this provider in the 55th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$695,197
Medicare patients
1,803
Services billed
11,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$111,054
Invega SustennaPaliperidone Palmitate32$88,212
Aripiprazole OdtAripiprazole38$60,930
VraylarCariprazine Hcl18$26,911
Risperidone OdtRisperidone128$23,492
Olanzapine OdtOlanzapine58$10,623
Doxepin Hcl28$7,748
Haloperidol181$7,702
Lurasidone Hcl53$6,101
Quetiapine Fumarate319$5,750
Divalproex Sodium206$5,326
Clozapine OdtClozapine11$4,471
Aripiprazole45$3,977
DayvigoLemborexant11$3,782
Lorazepam432$3,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$47$111,05418 claims
Johnson & JohnsonInvega Sustenna$59$88,21232 claims
AbbVieVraylar$98$26,91118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Brea

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →